TCG Labs Soleil, a company that creates focused biotechnology startups and prepares them for partnerships, announced on Thursday that it has raised $400 million in funding. This is the same amount it raised last year when it was first launched in partnership with The Column Group. The firm operates through two main parts: a venture fund called TCG Labs and an ongoing research hub called Soleil, which is run by a team of scientists. Together, they build and manage a group of companies, each focused on developing a single drug, and aim to secure partnerships once these drugs show promising early results. Biotech companies can take different approaches, from developing broad drug platforms to focusing on just one drug. While broader strategies can offer bigger rewards, they also require more time and money. Single-drug startups, on the other hand, can move faster and cost less, allowing for quicker decisions. TCG Labs Soleil believes its model helps make faster, more cost-effective choices, leading to better partnership deals. With this new funding, the company plans to keep building its portfolio and position each drug program for success, whether through further development or early partnerships. Since its start, TCG Labs Soleil has created 10 companies working on treatments for cancer, immune diseases, heart and metabolism disorders, and other conditions. Most of these companies are named after streets in San Francisco. In May, one of them, Juri Biosciences, secured a deal worth up to $210 million to license a prostate cancer treatment from a Chinese biotech company. The firm is led by Jin-Long Chen, the founder of NGM Biopharmaceuticals and a former research leader at Amgen. Over the past year, TCG Labs Soleil has expanded its research operations to Shanghai, adding to its original hub in South San Francisco, California. Jin-Long Chen noted that with several drug programs moving into clinical trials, this new funding reflects their progress and opens doors for more partnerships. Other venture firms in healthcare have also raised significant funding this year, including Omega Funds with $647 million and Deerfield Management with over $600 million.